PE20212154A1 - Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos - Google Patents

Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos

Info

Publication number
PE20212154A1
PE20212154A1 PE2021001510A PE2021001510A PE20212154A1 PE 20212154 A1 PE20212154 A1 PE 20212154A1 PE 2021001510 A PE2021001510 A PE 2021001510A PE 2021001510 A PE2021001510 A PE 2021001510A PE 20212154 A1 PE20212154 A1 PE 20212154A1
Authority
PE
Peru
Prior art keywords
alkyl
protein tyrosine
tyrosine phosphatase
compounds
cycloalkyl
Prior art date
Application number
PE2021001510A
Other languages
English (en)
Inventor
Andrew Bogdan
Geoff T Halvorsen
Elliot P Farney
Jennifer M Frost
Philip R Kym
Mark A Matulenko
Matthew O'connor
Reza Shiroodi
Eric Voight
Zhaoming Xiong
Qingwei Zhang
Christina Baumgartner
Jason Abbott
Christos Economou
Stacy Fosu
Original Assignee
Calico Life Sciences Llc
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc, Abbvie Inc filed Critical Calico Life Sciences Llc
Publication of PE20212154A1 publication Critical patent/PE20212154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Esta referido a compuestos de Formula I, en donde: Z es C(H)(R3 ), un enlace o N(R8 ); R1 es H, halogeno, alquilo, cicloalquilo, O-alquilo; R2 es H, alquilo, alquenilo, alquilo-O-, NH2, entre otras opciones; R2' es H, -NRaRb o -N(Ra )-N(Rb )-C(O)-fenilo; R4 es H, halogeno, alquilo, cicloalquilo, alquileno-hetrociclilo; R5 es H, deuterio, halogeno, alquilo, cicloalquilo, alquileno-heterociclilo; R6 y R7 son H, deuterio. Entre los compuestos preferidos tenemos los siguientes: 5-[1-fluoro-3-hidroxi-7-(3-metilbutoxi)-5,6,7,8-tetrahidronaftalen-2-il]-1?6 ,2,5-tiadiazolidina1,1,3-triona; 5-{7-[(2-ciclopropiletil)amino]-1-fluoro-3-hidroxi-5,6,7,8-tetrahidronaftalen-2-il}-1?6 ,2,5- tiadiazolidina-1,1,3-triona; entre otros. Estos compuestos son inhibidores de la proteina tirosina fosfatasa, por ejemplo, proteina tirosina fosfatasa no receptora tipo 2 (PTPN2) y/o proteina tirosina fosfatasa no receptora tipo 1 (PTPN1), tambien denominada proteina tirosina fosfatasa 1B (PTP1B)). Estos compuestos se emplean en el tratamiento de enfermedades o trastornos como por ejemplo, cancer, diabetes tipo 2, obesidad, una enfermedad metabolica, o cualquier otra enfermedad, trastorno o dolencia que responda favorablemente al tratamiento con un inhibidor de PTPN2 o PTPN1
PE2021001510A 2019-03-14 2020-03-13 Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos PE20212154A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818447P 2019-03-14 2019-03-14
PCT/US2020/022717 WO2020186199A1 (en) 2019-03-14 2020-03-13 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20212154A1 true PE20212154A1 (es) 2021-11-09

Family

ID=70190226

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001510A PE20212154A1 (es) 2019-03-14 2020-03-13 Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos

Country Status (22)

Country Link
US (1) US10851073B2 (es)
EP (1) EP3938038A1 (es)
JP (2) JP7204005B2 (es)
KR (2) KR102533599B1 (es)
CN (2) CN116332873A (es)
AR (1) AR118374A1 (es)
AU (1) AU2020234712A1 (es)
BR (1) BR112021017430A2 (es)
CA (1) CA3131894A1 (es)
CL (1) CL2021002382A1 (es)
CO (1) CO2021013524A2 (es)
CR (1) CR20210516A (es)
DO (1) DOP2021000188A (es)
EC (1) ECSP21075909A (es)
IL (1) IL286373A (es)
MA (1) MA55301A (es)
MX (1) MX2021010544A (es)
PE (1) PE20212154A1 (es)
SG (1) SG11202109067PA (es)
TW (1) TW202100515A (es)
UY (1) UY38613A (es)
WO (1) WO2020186199A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
IL305072A (en) * 2021-02-12 2023-10-01 Recovery Therapeutics Inc Materials, compositions and methods for modulating FGF activity
AU2022234402A1 (en) * 2021-03-11 2023-09-28 Kumquat Biosciences Inc. Heterocycles and uses thereof
WO2022261145A1 (en) * 2021-06-10 2022-12-15 Ness Therapeutics, Inc. Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
WO2023086495A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023086498A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
TW202337459A (zh) * 2022-02-02 2023-10-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150523A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023179542A1 (en) * 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2463615C (en) 2001-10-30 2011-07-26 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
KR20080110882A (ko) 2006-03-31 2008-12-19 노파르티스 아게 ＰＴＰａｓｅ의 티아디아졸리디논 억제제
WO2008142198A2 (en) 2007-05-23 2008-11-27 Valtion Teknillinen Tutkimuskeskus A method for inhibiting or stimulating angiogenesis in an individual
AR066820A1 (es) 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
US20130202577A1 (en) 2010-02-03 2013-08-08 Monash University Diagnostic and prognostic assay for breast cancer
CA2977839C (en) 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
EP3154555A4 (en) 2014-06-10 2018-02-28 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
CA3073755A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill Universit Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp)
TW202016082A (zh) 2018-06-21 2020-05-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法

Also Published As

Publication number Publication date
BR112021017430A2 (pt) 2022-01-18
US10851073B2 (en) 2020-12-01
CO2021013524A2 (es) 2022-02-28
CR20210516A (es) 2022-07-19
WO2020186199A1 (en) 2020-09-17
UY38613A (es) 2020-09-30
IL286373A (en) 2021-10-31
CN114025844B (zh) 2022-07-26
CN116332873A (zh) 2023-06-27
ECSP21075909A (es) 2021-11-30
CL2021002382A1 (es) 2022-06-03
US20200299246A1 (en) 2020-09-24
KR102533599B1 (ko) 2023-05-17
CA3131894A1 (en) 2020-09-17
EP3938038A1 (en) 2022-01-19
DOP2021000188A (es) 2022-03-15
JP2023052094A (ja) 2023-04-11
JP2022522526A (ja) 2022-04-19
MX2021010544A (es) 2021-10-01
KR20230074822A (ko) 2023-05-31
AR118374A1 (es) 2021-09-29
SG11202109067PA (en) 2021-09-29
TW202100515A (zh) 2021-01-01
JP7204005B2 (ja) 2023-01-13
AU2020234712A1 (en) 2021-09-09
MA55301A (fr) 2022-01-19
KR20210151821A (ko) 2021-12-14
CN114025844A (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
PE20212154A1 (es) Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CO2020009625A2 (es) Inhibidor de fap
CO2021015030A2 (es) Inhibidores del inflamasoma nlrp3
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
CL2018000292A1 (es) Compuestos farmacéuticos
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
PE20180462A1 (es) Moduladores cot y metodos de uso de los mismos
EA202091709A1 (ru) Ингибиторы днк-пк
BRPI0808888B8 (pt) composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
MA52856B1 (fr) Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
PE20141974A1 (es) Compuestos de heterociclilo
PE20161292A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
ECSP044935A (es) Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
BR112022002059A2 (pt) Formas sólidas de um inibidor de hpk1
PE20151776A1 (es) Compuestos de heteroarilo y sus usos
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
BRPI0606281A2 (pt) compostos orgánicos
EA202090124A1 (ru) Аденовирус, вооруженный биспецифическим рекрутером t-клеток (bite)
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA202091708A1 (ru) Ингибиторы днк-пк